iBio Stock
iBio, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Martin Brenner
- Employees
- 23
- Market cap
- $49 M
- IPO
- 19/08/2008
iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is…
iBio stock: price history
1D
-2.1%
1W
-12.0%
1M
-35.1%
6M
-62.8%
YTD
-60.3%
1Y
-9.4%
2Y
-73.1%
5Y
-99.8%
10Y
-100.0%
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~11% weaker price swings than usual
Ask the agents about iBio
Analyst assessment of iBio
PRICE TARGET LOW
US$5.00
CONSENSUS
US$5.00
MEDIAN
US$5.00
PRICE TARGET HIGH
US$5.00
0
STRONG BUY
3
BUY
1
HOLD
0
SELL
0
STRONG SELL
4
TOTAL · Buy
As of: 02/07/2026
iBio stock metrics
P/E
-2.36
P/B
0.93
EV/EBITDA
0.15
RETURN ON EQUITY
-12.4%
NET MARGIN
0.0%
DEBT/EQUITY
0.03
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
86.5%
FLOAT SHARES
55,657,920
AVG. DAILY VOLUME (30D)
725,841
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about iBio stock
What does iBio do?
iBio, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Martin Brenner, the company employs around 23 people.
The IPO was on 19/08/2008; the stock trades on NASDAQ under the ticker IBIO.
What do analysts say about iBio stock?
4 analysts rate the stock, the consensus is Buy (as of 02/07/2026).
The average price target is US$5.00, ranging from US$5.00 to US$5.00, with a median of US$5.00.
This is an external assessment, not a statement by Market Jury.
When does iBio report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly -11% stronger than usual.
Does iBio pay a dividend?
No, iBio currently does not pay a dividend.
Which stocks are comparable to iBio?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get iBio stock analyzed?
Clicking "Analyze stock" lets five strategies assess iBio against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.